

2025 Virtual Patient & Caregiver Education Conference

Saturday, July 26, 2025 11 a.m. – 4 p.m. ET

> Presented by Co-sponsors

BREAKTHROUGHS TODAY CURES TOMORROW





Comprehensive Cancer Center

Additional support provided by









TABLE OF CONTENTS

Scroll or click on the text or logos below to navigate to sections of the booklet. To return to the Table of Contents, click the round red TOC button at the end of each section. For optimal interactive performance, view this document in Read Mode.

22	WELCOME
	AGENDA
?	ASK QUESTIONS DURING THE CONFERENCE USING SLIDO7
	FAST FACTS ABOUT NETS
	SPEAKER BIOGRAPHIES 11-14
	FROM OUR SPONSORS 16-22
	CLINICAL TRIALS
B	SUPPORT NETRF
Thank You	A WORD OF THANKS

Note to Attendees

This patient and caregiver education conference is not intended as and shall not be relied upon as medical advice. The Neuroendocrine Tumor Research Foundation encourages all users to discuss any information provided with their oncologist, physician, and/or appropriate qualified health professional.

Attending this conference does not constitute a patient-physician relationship. The Neuroendocrine Tumor Research Foundation does not represent that any information provided here should supplant the reasoned, informed advice of a patient's oncologist, physician, and/or appropriate qualified health professional.

WELCOME

We are honored to welcome you to the 2025 KNOW YOUR NETs Virtual Patient and Caregiver Education Conference during a landmark year. This is not only the 6th annual KNOW YOUR NETs Virtual Conference, this year also marks NETRF's 20th anniversary of driving research discoveries and supporting neuroendocrine cancer patients and caregivers. We're proud of what we've achieved together, and we're committed to continuing to offer standout educational programming for the neuroendocrine cancer community.

Thanks to your input, the agenda is designed to align with your interests. We are fortunate to have a group of outstanding speakers—all experts in their fields—who have generously given their time to participate in this program.

You can submit your questions for our panel through SLIDO.com, using the event code NETRF. See the instructions for SLIDO in this booklet.

NETRF is grateful for all of our conference sponsors who have helped make this event possible. Please take a moment to review the educational content from our sponsors in this booklet. If you are looking for more information, check out NETRF's online <u>NET Knowledge Center</u>.

Thank you for joining us today, supporting NETRF and, most importantly, being an active and engaged participant and community member. Your story matters and you are not alone. Together, we are committed to increasing understanding of neuroendocrine cancer for patients and their loved ones.



Elyse Gellerman, MHS Conference Co-Chair CEO Neuroendocrine Tumor Research Foundation



Xavier Keutgen, MD Conference Co-Chair Associate Professor of Surgery UChicago Medicine



AGENDA

Pre- conference	The 2025 Know Your NETs Preconference Video: NETs and NECs 101 To be emailed one week prior to the conference.
conference	Kimberly Perez, MD, Dana-Farber Cancer Institute
11:00 a.m.	Welcome and Introduction:
	Elyse Gellerman, MHS, Chief Executive Officer, NETRF
	Xavier Keutgen, MD, FACS, UChicago Medicine
Advancing K	nowledge: Breakthroughs in Research and Innovation
11:20 a.m.	Expanding Possibilities with Recent Developments Jennifer Eads, MD, Penn Medicine
11:40 a.m.	Recent Advances Now Used in Clinic
	Chih-Yi (Andy) Liao, MD, UChicago Medicine
	Abdul Khan, MD, UChicago Medicine
12:00 p.m.	Understanding Tumor Biology
	Thor Halfdanarson, MD, Mayo Clinic
12:20 p.m.	Sequencing Therapies for Liver Metastases and Advanced Disease
	Xavier Keutgen, MD, FACS, UChicago Medicine
	Abdul Khan, MD, UChicago Medicine
12:40 p.m.	Thrivership Reflection
Break	
Advancing C	are: Treatment and Teamwork
12:50 p.m.	Tackling the Unusual NETs
	Jaydira Del Rivero, MD, National Cancer Institute
1:10 p.m.	Tumor Board
	Jennifer Eads, MD, Penn Medicine
	Thor Halfdanarson, MD, Mayo Clinic
	Xavier Keutgen, MD, FACS, UChicago Medicine
	Abdul Khan, MD, UChicago Medicine Chih-Yi (Andy) Liao, MD, UChicago Medicine
	Heloisa Soares, MD, PhD, Huntsman Cancer Institute, University of Utah
	Chandrikha Chandrasekharan, MBBS, MD Anderson Cancer Center
2:00 p.m.	Thrivership Reflection
Break	

Agenda continued on page 4.

Program subject to change.



Empowering Lives: Thriving Through Knowledge, Wellness, and Advocacy		
2:10 p.m.	Managing Symptoms & Enhancing Daily Life Heloisa Soares, MD, PhD, Huntsman Cancer Institute, University of Utah	
2:30 p.m.	Genetics, Risk Factors, and Survivorship Beyond Diagnosis Chandrikha Chandrasekharan, MBBS, MD Anderson Cancer Center	
2:50 p.m.	Advancing and Strengthening Research Anna Greene, PhD, Director of Research, NETRF	
3:10 p.m.	Living Fully with Neuroendocrine Cancer Jessica Thomas, LCSW, Director of Patient Education, NETRF	
3:30 p.m.	Live Q&A Panel Jennifer Eads, MD, Penn Medicine Anna Greene, PhD, Director of Research, NETRF Thor Halfdanarson, MD, Mayo Clinic Xavier Keutgen, MD, FACS, UChicago Medicine Abdul Khan MD, UChicago Medicine Chih-Yi (Andy) Liao, MD, UChicago Medicine Jaydira Del Rivero, MD, National Cancer Institute Kimberly Perez, MD, Dana-Farber Cancer Institute Chandrikha Chandrasekharan, MBBS, MD Anderson Cancer Center	
4:00 p.m.	Closing Remarks	

Program subject to change.

Presented by Co-sponsors







Comprehensive Cancer Center

Additional support provided by

















BECOME INFORMED, ENGAGED AND CONNECTED IN YOUR NET JOURNEY

Current and accurate patient education and information is vital to helping you live well with neuroendocrine cancer. We know that finding credible information and education can be challenging and difficult to navigate.

NETRF's NET Knowledge Center is a comprehensive resource organized to direct you to the information you need to be engaged in your neuroendocrine cancer journey while connecting you to a community of resources.

INFORMATION

Learn more about neuroendocrine cancers

A diagnosis of a neuroendocrine tumor often comes with many questions and concerns. These resources explain the various types of neuroendocrine cancers, diagnostic tests, and risks so you and your family can better understand your condition.

ENGAGEMENT

Take the next step regarding your diagnosis

With many different kinds of neuroendocrine cancers, it's important to find the best possible care and treatment. These resources explore finding specialists, treatments, and how best to care for yourself.

COMMUNITY

Connect with more people and resources about neuroendocrine cancer

When it comes to neuroendocrine tumors, it takes a community. Explore the many ways you can access the latest information on treatments and research progress, and what's happening in the neuroendocrine cancer community.



Visit the NET Knowledge Center at <u>netrf.org/for-patients/</u> or scan this QR code.



Neuroendocrine Cancer: A Guide for Patients and Families



NEUROENDOCRINE CANCER

A guide for patients and families

NETRF's 80-page guide to neuroendocrine cancer is a hands-on reference for the tests, treatments, and management of gastrointestinal, pancreatic, lung, and adrenal neuroendocrine tumors. It offers a solid overview of neuroendocrine cancer for the recently diagnosed patient, serves as a helpful reference for longer-term survivors, and gives practical tips on managing symptoms, and patient/provider communication for those at any stage of the disease.

The NETRF Patient Guide is made possible through the generous support from the Vincent E. Taylor Education Fund.

To order your copy visit, <u>netrf.org/for-patients/</u> or scan the QR code here:





ASK QUESTIONS ONLINE THROUGH SLIDO!

OPTION 1


- On your phone, tablet, or computer, open your web browser and go to <u>www.slido.com</u>, then select our event code: NETRF (screen 1)
- Click on Live Interaction (screen 2). That's it! You are ready to ask a question or vote a question up (screen 3). There's no need to duplicate a question.

OPTION 2

• Click <u>this link</u> to automatically go to the Questions page.

Do NOT use your name. Please ask your question anonymously or use your initials.

While we cannot guarantee your question will be addressed, questions with the highest number of votes stand a better chance of getting answered by a speaker.



Fast Facts About NETs

- Neuroendocrine cancer is an uncommon cancer and the incidence has been increasing in recent decades. This is attributed in part to improvements in diagnostic techniques and greater awareness.
- More than **12,000 people** in the U.S. are diagnosed with a neuroendocrine cancer each year.
- The average length of time from first symptoms to diagnosis is **4.3 years**.¹
- The average number of health care visits made before a neuroendocrine cancer diagnosis is
 11.8 visits.¹
- Up to **58% of patients** had metastases at diagnosis.



ABOUT THE NEUROENDOCRINE TUMOR RESEARCH FOUNDATION (NETRF)


The Neuroendocrine Tumor Research Foundation is the largest global funder of neuroendocrine cancer research, investing \$40 million in landmark research since 2005. NETRF's mission is to drive transformational discoveries in the study of neuroendocrine tumors. We are leading the fight to bring life-changing treatments to families and to find a cure.



NETRF:

- Invests boldly in the most promising scientific projects worldwide
- Funds and nurtures the most brilliant NET scientists who bring their original thinking and determined spirit to their work
- Offers hope to patients and families
- Shapes the future of neuroendocrine cancer care to save lives

NETRF's impact on the field of neuroendocrine cancer research has been profound. Thanks to NETRF-funded discoveries and the efforts of the neuroendocrine cancer medical community, the therapeutic landscape of neuroendocrine cancer management looks entirely different now than it did in 2005, when NETRF began. Such advances are not random. They are the direct result of many years of NETRF-funded research.





View our 2024 Annual Report to see the impact we have had and a timeline commemorating 20 years of driving breakthroughs.



EDUCATING AND EMPOWERING PATIENTS

NETRF is dedicated to the thousands of patients, families, and caregivers affected by neuroendocrine cancer. We provide expert educational resources to help you understand your diagnosis, make informed health care decisions, and thrive.

Our resources include:



NET Knowledge Center

A comprehensive online resource for information, engagement, and community building



Neuroendocrine Cancer Guide

A hands-on reference for the tests, treatments, and management of neuroendocrine cancer



NETWise Podcast series

Insights and perspectives on living with neuroendocrine cancer



NETRF YouTube library

Videos about diagnosis, treatment, research, and living with neuroendocrine cancer



Patient and caregiver education conferences In-person and virtual events for knowledge- and community-building



Searchable databases

Includes neuroendocrine cancer doctors and multidisciplinary treatment programs



SPEAKER BIOGRAPHIES



Elyse Gellerman, MHS

Chief Executive Officer, NETRF

Elyse has been Chief Executive Officer of the Neuroendocrine Tumor Research Foundation since November 2017. As CEO, she has built a team that has vastly expanded NETRF's global reach in research funding and patient education. Prior to NETRF, Elyse was a Regional Vice President for Sarah Cannon, the oncology service line for Hospital Corporation of America (HCA). Elyse spent more than 20 years in hospital service line development, operations consulting, and marketing. She has served on the national board at Susan B. Komen, and been a member of other health-related nonprofit boards. In 2011, Elyse was recognized by the Obama Administration as a Champion for Change in the fight against breast cancer. Elyse graduated from Cornell University and has a master's degree in healthcare systems from the University of Denver.



Xavier Keutgen, MD

UChicago Medicine

Dr. Keutgen is a surgical oncologist with particular expertise in treating neuroendocrine, thyroid, parathyroid and adrenal tumors. He is the director of the University of Chicago Neuroendocrine Tumor Center and works closely with a multidisciplinary team that specializes in NETs. Dr. Keutgen, a Belgium native, received his medical degree from the University of Heidelberg (Germany), and completed his residency at New York Presbyterian Hospital-Weill Cornell Medical Center and fellowships at the University of Zurich (Switzerland) and the National Cancer Institute (NIH).



Chandrikha Chandrasekharan, MBBS, MD

MD Anderson Cancer Center

Dr. Chandrasekharan is a Clinical Associate Professor at MD Anderson Cancer Center, where she has focused on neuroendocrine tumors and pancreatic cancer since January 2025. She is a dual board-certified physician in Medical Oncology and Palliative Medicine. Prior to joining MD Anderson, Dr. Chandrasekharan served for eight years as a Clinical Associate Professor at the University of Iowa. There, she co-led the gastrointestinal oncology program and treated a broad range of GI malignancies. From 2021 to 2022, she was Co-Director of the Clinical Core for the Neuroendocrine Tumor SPORE. She is an active member of the North American Neuroendocrine Tumor Society (NANETS), currently serving as Co-Chair of the NANETS Annual Symposium Planning Committee, and previously chaired the Regional Medical Education Committee. In addition to her clinical and academic work, Dr. Chandrasekharan is engaged in clinical trials and research focused on healthcare outcomes, health equity, and global oncology care.



SPEAKER BIOGRAPHIES, cont.



Jaydira Del Rivero, MD

National Cancer Institute

Dr. Del Rivero is the endocrine oncologist at the Developmental Therapeutics Branch, NCI/NIH. She serves as the principal investigator of the Natural History Study for Neuroendocrine Tumor and Adrenocortical Cancer, which aims to provide the basis for developing therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient-reported outcome measures. Her efforts focus on developing novel treatment approaches and targeted therapies for endocrine malignancies like advanced gastroenteropancreatic neuroendocrine tumors, adrenal cancer, and pheochromocytoma/paraganglioma, and she leads treatment trials at the NCI. Dr. Del Rivero served on the Board of Directors of NANETS and chaired the Guidelines Committee. She is a member of the NCI NET Task Force. Dr. Del Rivero currently is the co-chair of the NANETS NETPACT and the co-chair of the NIH Rare Endocrine-Neuroendocrine Cancers SIG.



Jennifer Eads, MD

Penn Medicine

Dr. Jennifer Eads is a Professor of Medicine and gastrointestinal medical oncologist at the University of Pennsylvania, Abramson Cancer Center where she serves as the physician lead for GI clinical research, is the Director of the Penn Neuroendocrine Tumor Program and is the Director of the Penn National Clinical Trials Network. She focuses on the clinical care of patients with neuroendocrine tumors and is also an active clinical researcher in this area, having led multiple phase I, II and III clinical trials. Nationally she is a member of the Eastern Cooperative Oncology Group where she has been a study chair on several trials and in 2022 was named the ECOG-ACRIN Young Investigator of the Year. She has also been on the Neuroendocrine Guidelines Panel for the National Comprehensive Cancer Network, has been on the Board of Directors for NANETS, and is currently on the Board of Scientific Advisors for the Neuroendocrine Tumor Research Foundation.



Anna Greene, PhD

Director of Research, NETRF

As NETRF's Director of Research, Dr. Greene leads the foundation's research programs, oversees the annual grant cycle, supervises post-award processes, organizes the annual research symposium, and reports research impact and outcomes to the community. She is motivated to help advance neuroendocrine cancer research to understand the disease better and ultimately identify better treatments and cures. She earned a BS in chemistry from Berry College and a PhD in chemistry from Dartmouth College.

SPEAKER BIOGRAPHIES, cont.



Thor Halfdanarson, MD

Mayo Clinic


Dr. Halfdanarson is a professor of Oncology at the Mayo Clinic College of Medicine and Science and a consultant in Medical Oncology at the Mayo Clinic. He specializes in GI oncology with a focus on NETs and cancers of unknown primary site, serves as the Associate Medical Director of the Cancer Clinical Trials Office at the Mayo Clinic Comprehensive Cancer Center and is the co-chair of the Pancreatic/Neuroendocrine Tumor Board. Dr. Halfdanarson is a member of the NCCN Guidelines Panel for NETs, the Co-Chair of the NET Group at Alliance for Clinical Trials in Oncology and the current Vice President of NANETS.



Abdul Khan, MD

UChicago Medicine

Dr. Khan is an Assistant Professor of Radiology at the University of Chicago. He is an interventional radiologist who specializes in minimally invasive interventions related to hepatobiliary diseases. The majority of his time is spent practicing interventional oncology by helping diagnose and treat hepatobiliary tumors as well as providing symptom relief from cancer-related pain using image guided, minimally invasive procedures.



Chih-Yi (Andy) Liao, MD

UChicago Medicine

Dr. Liao is an Associate Professor of Medicine at the University of Chicago. He is a medical oncologist and clinical investigator who specializes in treating gastrointestinal neuroendocrine tumors and hepatobiliary cancers. He leads and conducts many clinical trials for these cancers. He serves as the Medical Director of the University of Chicago's Hematology/Oncology Clinic, the Interim Director of the Gastrointestinal Oncology Program and the Co-Director of the Neuroendocrine Tumor Program.



Kimberly Perez, MD

Dana-Farber Cancer Institute

Dr. Perez is an Assistant Professor of Medicine at Harvard Medical School and Senior Physician and Co-Director of Gastrointestinal Oncology Clinical Trials Program at Dana-Farber Cancer Institute in Boston. She is a medical oncologist and clinical investigator who specializes in inherited cancer syndromes and treatment of neuroendocrine and pancreaticobiliary cancers. She serves as the principal investigator of many clinical trials for these cancers.



SPEAKER BIOGRAPHIES, cont.



Heloisa Soares, MD, PhD

Huntsman Cancer Institute, University of Utah

Dr. Soares is a medical oncologist with a focus in gastrointestinal and neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at University of Utah, where she leads the University of Utah NET Destination Care Program. She serves as the medical director for the Clinical Trials Office as well as the co-physician leader in the GI Clinical Trials Research Group at HCI. In 2019, she was elected as a member of the board of directors for NANETS and served on the board until 2023 and now chairs the newly created NETPACT committee. Additionally, she is the co-chair for the NCI NET taskforce and is a panel member for the Neuroendocrine and Adrenal Tumors NCCN Clinical Practice Guidelines in Oncology.




Jessica Thomas, LCSW

Director of Patient Education, NETRF

Jessica Thomas, LCSW, is a clinical social worker with nearly 20 years of experience supporting patients and caregivers navigating neurology, oncology, and chronic illness. With a career rooted in mental health care for those facing complex medical conditions, Jessica is deeply committed to helping individuals and families identify and embrace what matters most to them while living with chronic, progressive, or terminal illness. She is passionate about fostering community, advancing patient-centered care, supporting research, and improving the overall patient experience and outcomes.







A Podcast About Neuroendocrine Cancer

Being diagnosed with neuroendocrine cancer, an uncommon disease, can feel isolating and overwhelming. The NETWise podcast is here to help patients and caregivers navigate the world of neuroendocrine tumors and carcinomas.

Listen as the NET Research Foundation (NETRF) speaks with experts and patients who will help you to understand diagnosis, treatment, thrivership and everything in between. NETWise is for everyone, from newly diagnosed patients to longtime survivors, as well as caregivers and family members.

This is your guide to learning, listening, knowing, and being NETWise.

Check out these episodes for more on what you have heard during KNOW YOUR NETs:

- <u>Care for the Neuroendocrine Carcinoma Caregiver</u>
- <u>Understanding Neuroendocrine Carcinoma</u>
- Managing the Financial Burden of Neuroendocrine Cancer
- Radiopharmaceutical Treatment: FAQs and Insights
- How Could AI Change Neuroendocrine Cancer
- Finding Happiness While Living With Neuroendocrine Cancer
- Managing Symptoms of NENs

Subscribe <u>here</u> and find our entire NETWise library. Listen to NETWise wherever you get your podcasts.

Apple Podcasts





Neuroendocrine Tumor Research Foundation 100 Hancock Street, Third Floor Quincy, MA 02171 (617) 946-1780 | netrf.org





Neuroendocrine Tumor Program

UChicago Medicine

Comprehensive Cancer Center

One of the highest volume centers in the country, the **University of Chicago Medicine Neuroendocrine Tumor (NET) Program**

offers unique therapy options for even the most advanced cancers. We offer:

- A multidisciplinary program consisting of nationally recognized experts who specialize in diagnosing and treating all forms of NETs.
- A multidisciplinary in-person and virtual clinic that allows you to be seen by our oncologists and surgeons at the same time.
- A dedicated NET nurse navigator to guide you through the program and facilitate your treatment plan in collaboration between specialists.
- The most advanced surgical techniques, including minimally invasive/robotic procedures and complex approaches to remove and destroy NETs that have spread to the liver.
- Leading-edge technologies like precision-enhancing navigationcontrolled ablation of liver tumors and liver tumor histotripsy.
- The only medical cyclotron in the region for creating novel radiotracers for NETs, which helps create next-generation PRRT treatments in-house.
- Molecular profiling of NETs allowing for a personalized approach using therapies that work best on your tumor.
- One of the most experienced genetic counseling programs in the country to treat patients with NETs linked to hereditary conditions.
- Researchers conducting the latest studies on NETs, both in the laboratory and the clinic.







Population research



Translational research



Cancer genetics and immunotherapy



New treatments, early phase clinical trials



Recognized as an NCI Designated Comprehensive Cancer Center

UChicago Medicine is also recognized for the comprehensive nature of our research, care, education and community outreach programs. We are one of only two institutions in the state of Illinois — and 51 in the United States — to be recognized as a comprehensive cancer center. In addition, we have been named as a member institution of the National Comprehensive Cancer Network (NCCN), an alliance of 33 leading cancer centers in the United States.






Meet the Neuroendocrine Tumor Team



Xavier Keutgen, MD Endocrine Surgery



Daniel Appelbaum, MD Nuclear Medicine



Chih-Yi Liao, MD Hematology and Oncology (Cancer)



Uzma D. Siddiqui, MD Interventional Endoscopy and Gastroenterology



Abdul Khan, MD Radiology



Namrata Setia, MD Pathology

Get a Second Opinion

Seeking the opinion of an expert can ease your mind and help you feel more secure in the decisions you are making. At UChicago Medicine, we offer both onsite and remote second opinions. In addition to recommending standard therapies, our physicians may also offer innovative treatment options not widely available at most hospitals. including clinical trials that may be right for you.

To learn more, call 1-855-702-8222 or visit UChicagoMedicine. org/cancerappointment.



Our dedicated nurse navigator will guide you through the program and facilitate your treatment plan in collaboration with our multidisciplinary team.

To make an appointment, call 800-824-0200 or email NETS@uchospitals.edu





CONNECT with Crinetics Patient Advocacy

Patients are at the heart of everything we do at Crinetics.

We deeply value our partnerships with advocacy groups and members of the patient community.

Our advocacy team is dedicated to listening, learning, and integrating patient insights to enhance every step of Crinetics' drug discovery and development journey.



SCAN to sign up with Crinetics Patient Advocacy and stay connected



Crinetics Pharmaceuticals is a global, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of the next generation of therapeutics for patients with endocrine and endocrine-related diseases.

CUCIUM[®] is proud to sponsor 2025 NETRF Know Your NETs Virtual Education Conference

At Curium, we've been committed to supporting the neuroendocrine tumor (NET) community for over 30 years. We believe in the power of education, advocacy, and access—and we're honored to continue that mission by sponsoring this important event.

By partnering with NETRF, we're proud to help bring trusted information directly to patients, caregivers, and healthcare professionals—so they can better understand, manage, and navigate the NET journey.



Together, we're advancing care. One patient at a time.



EXELIXIS[®]



DECAUSE

We innovate medicines for life.

exelixis.com





RayzeBio, A Bristol Myers Squibb Company, is proud to support the NETRF Know Your NETs 2025 Conference

Discovering and Developing Radiopharmaceuticals for Patients Living with Cancer

At RayzeBio, A Bristol Myers Squibb Company, we are focused on creating precision radiopharmaceutical therapies (RPTs) that transform people's lives. Despite therapeutic advances made in the last decade, there remains a high unmet need for new cancer treatments. We believe RPT represents one of the most promising new modalities for the treatment of solid tumors.

Every patient deserves access to the best possible treatment, and we're committed to making a difference in the lives of people with cancer. RPTs are positioned to revolutionize the treatment of cancer. RayzeBio is committed to harnessing the power of targeted radioisotopes to focus on improving survival of people living with cancer.



Learn more about RayzeBio at www.rayzebio.com





Visit myNETjourney.com

A NET patient resource from ITM USA, Inc.

Please visit myNETjourney.com to learn more about a resource for people with neuroendocrine tumors (NETs). With myNETjourney.com, ITM USA aims to **support you in your journey ahead!**

This site provides tools and advice on NET. It connects you with resources to help and empower you to engage in your care.







Resources for family and friends



Scan the QR code above and bookmark **myNETjourney.com** to your home screen.

© 2025 ITM USA, Inc. ITM USA, Inc. | Princeton, NJ 08540 Web: www.itm-radiopharma.com Email: info@itm-radiopharma.com Phone: +1 (609) 785-5849




CLINICAL TRIALS



Clinical trials can provide patients with innovative treatments and are the final step in a long process that begins with research in a lab. Before any new treatment is used in people in clinical trials, researchers work for many years in the lab to understand its effects by testing it first on cells or in animals. They then work to determine the best dose for treatment, the side effects the drug may cause, and how the effectiveness of the drug compares to current treatments. It can take 10–15 years to develop a new drug to the point of a first clinical trial. Our online NET Trial Finder can connect you to clinical trials in your area.

NET Trial Finder





FIND A CLINICAL TRIAL

There are many clinical trials for neuroendocrine cancer. Scan this QR code to access the NET Trial Finder, or visit **netrf.org/for-patients/trial-finder/**



BREAKTHROUGHS TODAY CURES TOMORROW



Find it early. Treat it better. Cure it faster.



"I truly believe in the mission and the great work that NETRF is doing year in and year out. I want to be part of the solution — and I want to see a future where we find a cure."

- Steve Kaufer, NETRF Board Member, Co-Founder, TripAdvisor, Co-Founder, Give Freely

For 20 years, NETRF has led the global charge to transform neuroendocrine cancer treatment.

Now, we are launching our most ambitious campaign yet — a **\$25 million** effort to accelerate the bold science that will deliver new therapies and, ultimately, cures.

With your support, NETRF is advancing progress in three urgent and high-impact areas:

- **Early Detection** So patients are diagnosed sooner, when treatment is more effective
- New Therapeutic Development To expand treatment options and improve survival
- **Personalized Treatments** To ensure every patient receives the right care at the right time

Researchers are ready. Bold ideas are waiting. They just need our support.

Your Impact So Far:



\$40 million invested in breakthrough science

2 clinical trials fueled by NETRF-supported research

100 Hancock Street, Third Floor | Quincy, MA 02171 | (617) 946-1780 | netrf.org





This Is the Moment to Create Tomorrow's Cures

The discoveries happening today — in labs, clinics, and collaborative research teams – are transforming what's possible for patients and families facing neuroendocrine cancer.

But breakthroughs need you.

Early Detection

Your gift drives progress by:

- Funding life-changing research led by the world's leading scientists
- Powering innovations like CAR T-cell therapy from lab to lives
- Equipping patients and caregivers with trusted education and resources

As we mark 20 years of progress, let's celebrate by doubling down on our mission.

Make your gift today! Visit netrf.org/breakthroughs or scan the QR code to learn more.

Innovative



Robust Researche

ne

Breakthroughs Today, Cures Tomorrow. Our future starts now.

đ



****** TOC

RES

A WORD OF THANKS

Thank you for taking part in NETRF's 2025 KNOW YOUR NETs Virtual Patient and Caregiver Education Conference. We hope you found the sessions informative and valuable.

If you have any questions about NETRF, our research and resources, and how we can best support you on your journey with neuroendocrine cancer, please contact us at info@netrf.org.

We are grateful to our generous partners and friends like you. Thanks to your support, NETRF can host educational conferences and advance research, opening new doors to neuroendocrine cancer discoveries.

NETRF greatly appreciates the generosity of the following sponsors who made this educational program possible. Thank you!

